Stable Aqueous GLYX-13 Formulations for CNS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery methods for GLYX-13, a partial agonist of the NMDA receptor, face challenges in effectively crossing the blood-brain barrier and are susceptible to degradation in aqueous media, limiting its efficacy in treating CNS disorders such as depression, neuropathic pain, and anxiety.
Innovation Solution
Development of stable aqueous compositions for intravenous injection containing GLYX-13 or its salt, optimized with pH control and inclusion of pharmaceutically acceptable moieties like hydrochloric acid to enhance stability and bioavailability, ensuring efficient delivery to the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GLYX-13 is administered via conventional delivery methods, then it can reach the circulatory system, but it is susceptible to degradation in aqueous media and cannot effectively cross the blood-brain barrier
Solution Approach 1:
The patent changes the pH parameter of the aqueous composition to a specific range (pH 3.5-5.0) to stabilize GLYX-13 and prevent degradation. This parameter modification allows the peptide to maintain its structural integrity in aqueous media while remaining suitable for intravenous administration, thereby resolving the contradiction between stability and deliverability.
2Ease of operation
If GLYX-13 is formulated for intravenous injection, then it can be delivered to the circulatory system, but it degrades rapidly in aqueous composition
Solution Approach 1:
The patent modifies the chemical environment by adjusting pH to 3.5-5.0 and selecting specific excipients that prevent hydrolysis and degradation of GLYX-13. These parameter changes enable the formulation to be both chemically stable and suitable for intravenous injection, resolving the contradiction between administrability and compositional stability.
3Reliability
If the composition pH is adjusted to stabilize GLYX-13, then degradation is reduced, but the composition must maintain specific pH range for clinical safety
Solution Approach 1:
The patent identifies a specific pH window (3.5-5.0) that simultaneously provides optimal stability for GLYX-13 and remains compatible with clinical safety requirements. This precise parameter optimization allows the composition to achieve both enhanced stability and clinical adaptability, resolving the contradiction between these two requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions provide enhanced stability and bioavailability of GLYX-13, reducing degradation and improving its delivery to the brain, thereby improving treatment outcomes for CNS disorders.
Implementation Method 1
the stable, aqueous composition has a pH of from 3.9 to 5.5 at 25 °C; and wherein the acid provides chloride ions in the aqueous composition
Implementation Method 2
enhance clinical delivery or administration of the GLYX-13 peptide and/or salt thereof to the circulatory system by IV injection, thereby resulting in more efficient delivery of the GLYX peptide to the brain
Data Source
Figure 1~2
AI summary
The disclosure relates to intravenous formulations of GLYX peptides for treating CNS Disorders such as depression, neuropathic pain, or anxiety.